Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy

S. Forde, JD. Matthews, L. Jahangiri, LC. Lee, N. Prokoph, TIM. Malcolm, OT. Giger, N. Bell, H. Blair, A. O'Marcaigh, O. Smith, L. Kenner, S. Bomken, GAA. Burke, SD. Turner

. 2021 ; 192 (2) : 354-365. [pub] 20200903

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21019502

Grantová podpora
AHF1 Alex Hulme Foundation
Alex Hulme Foundation

Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019502
003      
CZ-PrNML
005      
20210830101102.0
007      
ta
008      
210728s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bjh.17043 $2 doi
035    __
$a (PubMed)32880915
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Forde, Sorcha $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
245    10
$a Paediatric Burkitt lymphoma patient-derived xenografts capture disease characteristics over time and are a model for therapy / $c S. Forde, JD. Matthews, L. Jahangiri, LC. Lee, N. Prokoph, TIM. Malcolm, OT. Giger, N. Bell, H. Blair, A. O'Marcaigh, O. Smith, L. Kenner, S. Bomken, GAA. Burke, SD. Turner
520    9_
$a Burkitt lymphoma (BL) accounts for almost two-thirds of all B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents and is characterised by a MYC translocation and rapid cell turnover. Intensive chemotherapeutic regimens have been developed in recent decades, including the lymphomes malins B (LMB) protocol, which have resulted in a survival rate in excess of 90%. Recent clinical trials have focused on immunochemotherapy, with the addition of rituximab to chemotherapeutic backbones, showing encouraging results. Despite these advances, relapse and refractory disease occurs in up to 10% of patients and salvage options for these carry a dismal prognosis. Efforts to better understand the molecular and functional characteristics driving relapse and refractory disease may help improve this prognosis. This study has established a paediatric BL patient-derived xenograft (PDX) resource which captures and maintains tumour heterogeneity, may be used to better characterise tumours and identify cell populations responsible for therapy resistance.
650    _2
$a zvířata $7 D000818
650    _2
$a Burkittův lymfom $x genetika $x patologie $x terapie $7 D002051
650    _2
$a dítě $7 D002648
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a regulace genové exprese u nádorů $7 D015972
650    _2
$a heterografty $x patologie $7 D064593
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a myši $7 D051379
650    _2
$a transplantace nádorů $7 D009368
650    _2
$a nádorové buňky kultivované $7 D014407
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Matthews, Jamie D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Jahangiri, Leila $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK $u Department of Life Sciences, Birmingham City University, Birmingham, UK
700    1_
$a Lee, Liam C $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Prokoph, Nina $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Malcolm, Tim I M $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Giger, Olivier T $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK
700    1_
$a Bell, Natalie $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
700    1_
$a Blair, Helen $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK
700    1_
$a O'Marcaigh, Aengus $u Children's Health Ireland at Crumlin, Dublin, Ireland
700    1_
$a Smith, Owen $u Children's Health Ireland at Crumlin, Dublin, Ireland
700    1_
$a Kenner, Lukas $u Department of Pathology, Medical University of Vienna, Vienna, Austria $u Unit of Laboratory Animal Pathology, University of Veterinary Medicine Vienna, Vienna, Austria $u Christian Doppler Laboratory for Applied Metabolomics, Vienna, Austria
700    1_
$a Bomken, Simon $u Wolfson Childhood Cancer Research Centre, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, UK $u The Great North Children's Hospital, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK $u Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
700    1_
$a Burke, Gladstone A A $u Department of Paediatric Oncology and Haematology, Addenbrooke's Hospital, Cambridge, UK
700    1_
$a Turner, Suzanne D $u Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Cambridge, UK $u Central European Institute of Technology, Masaryk University, Brno, Czech Republic
773    0_
$w MED00009374 $t British journal of haematology $x 1365-2141 $g Roč. 192, č. 2 (2021), s. 354-365
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32880915 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830101102 $b ABA008
999    __
$a ok $b bmc $g 1690348 $s 1139948
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 192 $c 2 $d 354-365 $e 20200903 $i 1365-2141 $m British journal of haematology $n Br J Haematol $x MED00009374
GRA    __
$a AHF1 $p Alex Hulme Foundation
GRA    __
$p Alex Hulme Foundation
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace